louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03009279: Relationship of Metabolic Syndrome and Its Components With Thyroid Nodule(s)
Official title: Relationship of Metabolic Syndrome and Its Components With Thyroid Nodule(s)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Metabolic Syndrome
Thyroid Nodule
Keywords: blood pressure
fasting plasma glucose
thyroid stimulating hormone
Lead sponsor: Qianfoshan Hospital
Sponsor class: OTHER
First posted: 2017-01-04
Enrollment: 10000
Sex: ALL
Minimum age (years): 15
Maximum age (years): 90
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Sampling method: NON_PROBABILITY_SAMPLE
Study population: People who received routain physical and laboratory examinations in the Health Management Cenre of QianFoShan Hospital from Jan. 2013 to Dec. 2015.

Brief summary: To investigate the association between metabolic syndrome (MS) and thyroid nodule(s).

Detailed description: To investigate the association between metabolic syndrome (MS), body mass index (BMI), hyperglycemia, dyslipidemia, hypertension and thyroid nodule(s) or thyroid functions in euthyroid subjects. Screen for the risk factors that affect the incidence of thyroid nodule(s).

Eligibility criteria: Inclusion Criteria:

1. People who received routain physical and laboratory examinations in the Health Management Cenre of QianFoShan Hospital from Jan. 2013 to Dec. 2015.
2. signed the informed consent.
3. Have complete clinical data.

Exclusion Criteria:

1. Patients with previous history of thyroid disease other than thyroid nodules.
2. People with abnormal thyroid function.
3. Thyroid ultrasound revealed patients with other lesions other than normal thyroid and thyroid nodules.
4. Pregnant or lactating women.

Primary outcomes:
measure: The laboratory examinations
timeFrame: In 2013-2015
Secondary outcomes:
measure: Blood pressure of patients in each group
timeFrame: In 2013-2015
Other outcomes:
measure: BMI of patients in each group
timeFrame: In 2013-2015
measure: Age of patients in each group
timeFrame: In 2013-2015
measure: Gender of patients in each group
timeFrame: In 2013-2015
Locations:
Study officials:
affiliation: Qianfoshan Hospital
name: Lin Liao
role: STUDY_CHAIR
References:
Clinical trial NCT04300179: Ewing Sarcoma Family of Tumors (ESFT): A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt
Official title: Ewing Sarcoma Family of Tumors (ESFT): A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Soft Tissue Neoplasms
Bone Neoplasms
Neoplasms
Keywords: Ewing's sarcoma (ES)
Peripheral primitive neuroectodermal tumor (PNET)
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2020-03-09
Enrollment: 59
Sex: ALL
Maximum age (years): 19
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pediatric cancer patients, those diagnosed with Ewing Sarcoma Family of Tumors (ESFT), in the period from 2000 January till 2015 December, and received treatment at the pediatric oncology department, their medical records will be retrospectively reviewed for data collection.

Brief summary: The aim of this study is to identify demographic \& disease characteristics in pediatric oncology patients diagnosed with Ewing Sarcoma Family of Tumors (ESFT) \& treatment outcomes in these patients.

Detailed description: Ewing sarcoma (ES) and peripheral primitive neuroectodermal tumor (PNET), Both entities that currently comprise the same spectrum of neoplastic diseases known as the Ewing sarcoma family of tumors (EFT), were originally described as distinct clinicopathologic entities. Primitive neuroectodermal tumors (PNETs) first described in 1918 by Stout as a malignant tumor arising from major nerve. Later, in 1921, ES was described as an undifferentiated tumor involving the diaphysis of long bones. It was also reported to arise in soft tissue (extraosseous ES). EFT is aggressive malignant small round cell tumors of bone and soft-tissue that predominantly affecting children and young adults.

Eligibility criteria: Inclusion Criteria:

* Patients whose age less than 19 years. Patients diagnosed with Ewing Sarcoma Family of Tumors (ESFT).

Exclusion Criteria:

* Patients whose age more than 19 years. Patients diagnosed with other bone \& soft tissue neoplasms.

Primary outcomes:
measure: Overall survival (OS)
timeFrame: From date of treatment initiation until the date of death from any cause or patients censored at last follow up, whichever came first, assessed up to 60 months
measure: Event Free Survival (EFS)
timeFrame: From date of treatment initiation until the date of event from any cause or patients censored at last follow up, whichever came first, assessed up to 60 months
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: South Egypt Cancer Institute
Study officials:
References:
Clinical trial NCT01948284: Comparing Maximal and Half-maximal Suction Pressure Applied During Water Exchange in Colonoscopy
Official title: A Randomized, Controlled Trial Comparing Maximal and Half-maximal Suction Pressure Applied During Water Exchange in Colonoscopy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Minimally Sedated Patient Undergoing Colonoscopy
Keywords: cecal intubation time
water exchange
pain
Lead sponsor: Dalin Tzu Chi General Hospital
Sponsor class: OTHER
Collaborators: name: Felix Leung, MD, Sepulveda Ambulatory Care Center, VAGLAHS
First posted: 2013-09-23
Enrollment: 74
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This prospective, randomize, controlled trial will compared maximal to half-maximal suction pressure applied during water exchange in patients undergoing minimally sedated colonoscopy. We test the hypothesis that maximal suction pressure is more efficient and causes shorter insertion time.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing minimally sedated colonoscopy performed by YHH

Exclusion Criteria:

* known history of obstructive lesions of the colon,
* allergy to meperidine,
* massive ascites,
* past history of partial colectomy, or
* refusal to provide written informed consent.

Primary outcomes:
measure: cecal intubation time
timeFrame: 30 minutes
Secondary outcomes:
measure: infused water amount
timeFrame: 30 minutes
measure: aspirated water amount
timeFrame: 30 minutes
measure: pain score
timeFrame: 30 minutes
measure: suction marks on the mucosa
timeFrame: 30 minutes
Other outcomes:
Locations:
city: Chia-Yi
country: Taiwan
facility: Buddhist Dalin Tzu Chi General Hospital
Study officials:
References:
citation: Leung FW, Amato A, Ell C, Friedland S, Harker JO, Hsieh YH, Leung JW, Mann SK, Paggi S, Pohl J, Radaelli F, Ramirez FC, Siao-Salera R, Terruzzi V. Water-aided colonoscopy: a systematic review. Gastrointest Endosc. 2012 Sep;76(3):657-66. doi: 10.1016/j.gie.2012.04.467.
citation: Leung J, Mann S, Siao-Salera R, Ransibrahmanakul K, Lim B, Canete W, Samson L, Gutierrez R, Leung FW. A randomized, controlled trial to confirm the beneficial effects of the water method on U.S. veterans undergoing colonoscopy with the option of on-demand sedation. Gastrointest Endosc. 2011 Jan;73(1):103-10. doi: 10.1016/j.gie.2010.09.020.
citation: Leung JW, Mann SK, Siao-Salera R, Ransibrahmanakul K, Lim B, Cabrera H, Canete W, Barredo P, Gutierrez R, Leung FW. A randomized, controlled comparison of warm water infusion in lieu of air insufflation versus air insufflation for aiding colonoscopy insertion in sedated patients undergoing colorectal cancer screening and surveillance. Gastrointest Endosc. 2009 Sep;70(3):505-10. doi: 10.1016/j.gie.2008.12.253. Epub 2009 Jun 24.
citation: Wasan SK, Schroy PC 3rd. Water-assisted unsedated colonoscopy: does the end justify the means? Gastrointest Endosc. 2009 Mar;69(3 Pt 1):551-3. doi: 10.1016/j.gie.2008.10.045. No abstract available.
Clinical trial NCT03001284: Multiple Sclerosis Produces Cardiovascular Subclinical Dysfunction
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Multiple Sclerosis
Lead sponsor: Carol Davila University of Medicine and Pharmacy
Sponsor class: OTHER
First posted: 2016-12-23
Enrollment: 103
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: te investigators enrolled prospectively patients with confirmed multiple sclerosis, diagnosed according to the revised McDonald's criteria\[8\], and control subjects, matched for age, gender, and presence of cardiovascular risk factors.

Brief summary: Multiple sclerosis (MS), debilitating disease involving primarily the central nervous system, may cause cardiovascular dysfunction, due to autonomous nervous system dysfunction, physical invalidity, increased oxidative stress, and systemic inflammatory status, but the detailed mechanisms are not elucidated. The investigators aimed to assess left and right ventricular (LV and RV) function, left atrial (LA) function, arterial function, and atrial-ventricular-arterial coupling in patients with MS, compared to control subjects. LV systolic and diastolic function and RV function were assessed by 2D- and 3D- echocardiography, tissue Doppler, and speckle tracking echocardiography. LA function was assessed by LA volume index and LA strain. Arterial remodeling and stiffness were assessed by intima media-thickness, pulse wave velocity, and parameters of wave intensity and endothelial function


Eligibility criteria: Inclusion Criteria:

1. age between 18 and 65 years;
2. patients with confirmed MS diagnosis, both newly diagnosed or already under immunomodulatory treatment;
3. informed consent signed.

Exclusion Criteria:

1. MS treated with mitoxantrone;
2. patients with known cardiovascular disease;
3. presence of other neurological conditions;
4. any renal, pulmonary, hepatic or hematological disease;
5. diabetes mellitus;
6. any degree of arterial hypertension;
7. pregnancy;
8. and difficult acoustic window

Primary outcomes:
measure: Left ventricle systolic dysfunction - by echocardiography
timeFrame: 1 year
measure: Right ventricle systolic dysfunction- by echocardiography
timeFrame: 1 year
measure: Left ventricular diastolic function - by echocardiography
timeFrame: 1 year
measure: arterial function - by vascular echography
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01118884: Effects of Oral Midazolam in Comparison Promethazine With Nitrous Oxide for Uncooperative Children
Official title: Sedative Effects of Oral Midazolam in Comparison Promethazine With Nitrous Oxide/Oxygen on Behavior Management of Uncooperative Children Receiving Dental Treatment
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Conscious Sedation
Keywords: Midazolam
Nitrous oxide
Behaviour management
Lead sponsor: Shahid Beheshti University
Sponsor class: OTHER
First posted: 2010-05-07
Enrollment: 20
Sex: ALL
Minimum age (years): 36
Maximum age (years): 96
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this study is to compare the safety and efficacy of sedation using orally administered midazolam and promethazine with nitrous oxide/oxygen in uncooperative children receiving dental treatments.

Detailed description: The effectiveness of oral midazolam in pediatric dentistry is controversial. Usefulness of midazolam alone is limited to short-duration procedures, and we are needed to identify safe oral conscious regiments which permit longer duration procedures in dental treatments especially in Pediatric dentistry.

Promethazine is a long-acting (4-12 hr) anti-histaminic, H1 antagonist drug which acts as a central nervous system depressant and showing itself to be a weak anxiolytic drug.

The hypothesis to be tested is whether promethazine would improve the patients behavior during dental procedures without affecting vital signs, thus enabling longer periods of moderate or conscious sedation.

Eligibility criteria: Inclusion Criteria:

* Healthy patients who are in ASA class 1 group
* Age of the patients must be between 36-96 months
* Uncooperative children who are in groups 1 or 2 according to Frankel's classification

Exclusion Criteria:

* Tonsil hypertrophy
* History of allergies
* Drooling or nocturnal snoring

Primary outcomes:
measure: Behavior change
timeFrame: during dental treatment which is 30 minutes after drug ingestion
Secondary outcomes:
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Dental school of Shahid Beheshti University of Medical Sciences
Study officials:
affiliation: Postgraduate student of Shahid Beheshti Medicine University
name: Sedighe Mozaffar
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01681784: Studies of Biomarkers in Female Lower Urinary Tract Symptoms
Official title: Studies of Biomarkers in Different Urodynamic Diagnoses of Female Patients With Lower Urinary Tract Symptoms
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Disorder of the Lower Urinary Tract
Keywords: lower urinary tract symptoms
biomarkers
urodynamic studies
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2012-09-10
Enrollment: 1000
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Female patients with lower urinary tract symptoms and underwent urodynamic studies

Brief summary: To determine the sensitivity and specificity of urinary NGF, PGE2, IL-6, EGF or combinations in diagnosing different urodynamic diagnoses.

Detailed description: Abstract

Background/Purpose:

Urodyamic study is an objective method to evaluate female patients with lower urinary tract symptoms (LUTS). However, this method includes place a urinary catheter, thus prevents it as a routine method to evaluate and follow up patients with LUTS. Therefore, it is necessary to find a simple and objective method to help in evaluating female patients with LUTS. Several kinds of biomarker had been reported in diagnosing patients with overactive bladder; however, the sensitivity remained poor. The aim of this study is to find a useful biomarker, biomarkers, or combinations, with the aid of urodynamic study, to objectively and precisely in evaluating the female patients with LUTS.

Patients and Methods:

We will perform a prospective study to recruit 300 female patients with LUTS at the outpatient clinic of Department of Obstetrics and Gynecology of National Taiwan University Hospital and Far Eastern Memorial Hospital.

All patients will be asked to complete OABSS, UDI-6 \& IIQ-7 questionnaires, voiding diary, 20-min pad test and urodynamic studies. Urinary nerve growth factor, prostaglandin E2, interleukin-6 and epidermal growth factor were also measured. Besides, we will also recruit 30 female patients without LUTS in our outpatient clinic, and they will be asked to complete the above questionnaire and examinations except pad test and urodynamic studies.

Possible Results:

With the comparison of the above parameters between non-LUTS and LUTS patients, we can answer the questions that (1) the mean values of urinary NGF, PGE2, IL-6, EGF in different urodynamic studies, (2) the sensitivity and specificity of urinary NGF, PGE2, IL-6, EGF or combinations in diagnosing different urodynamic diagnoses.

Eligibility criteria: Inclusion Criteria:

* Female patients with lower urinary tract symptoms

Exclusion Criteria:

* acute cystitis

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
References:
Clinical trial NCT00815984: Fractional Exhaled Nitric Oxide (FeNO) Result Prediction Factors in Children With Allergic Diseases
Official title: FeNO Result Prediction Factors in Children With Allergic Diseases
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Asthma
Allergic Rhinitis
Atopic Dermatitis
Keywords: Asthma
Allergic Rhinitis
Atopic Dermatitis
Children
lung function
skin prick tests
FeNO
Lead sponsor: Medical University of Lodz
Sponsor class: OTHER
First posted: 2008-12-31
Enrollment: 800
Sex: ALL
Minimum age (years): 5
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Children with asthma (allergic), and/or allergic rhinitis and/or atopic dermatitis

Brief summary: In about 800 children with allergic diseases (asthma, allergic rhinitis, atopic dermatitis) the investigators will retrospectively and cross-sectionally analyze the influence/correlation of diagnosis, treatment methods, allergy status (skin prick test results), lung function tests results on/with the concentration of nitric oxide in exhaled breath.

Detailed description: In about 800 children with allergic diseases from our Outpatient Clinic (asthma, allergic rhinitis, atopic dermatitis) we will retrospectively and cross-sectionally analyse the influence/correlation of diagnosis, treatment methods, allergy status (skin prick test results), lung function tests results on/with the concentration of nitric oxide in exhaled breath.

Eligibility criteria: Inclusion Criteria:

* Children with asthma (allergic), and/or allergic rhinitis and/or atopic dermatitis

Exclusion Criteria:

* Other chronic diseases
* Asthma exacerbation
* Pregnancy

Primary outcomes:
measure: Concentration of nitric oxide in exhaled breath.
timeFrame: 1-4 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lodz
country: Poland
facility: Department of Pediatrics and Allergy, N. Copernicus Hospital
Study officials:
affiliation: Department of Pediatrics and Allergy, N. Copernicus Hospital, Lodz, Poland
name: Iwona Stelmach, MD PhD Prof
role: STUDY_CHAIR
affiliation: Department of Pediatrics and Allergy, N. Copernicus Hospital, Lodz, Poland
name: Tomasz Grzelewski, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Grzelewski T, Majak P, Jerzynska J, Stelmach W, Stelmach R, Janas A, Grzelewska A, Witkowski K, Makandjou-Ola E, Stelmach I. The interpretation of exhaled nitric oxide values in children with asthma depends on the degree of bronchoconstriction and the levels of asthma severity. Respir Care. 2014 Sep;59(9):1404-11. doi: 10.4187/respcare.02889. Epub 2013 Dec 31.
Clinical trial NCT04106284: Comorbidities of Epilepsy
Official title: Comorbidities of Epilepsy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Epilepsy
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2019-09-27
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects included will be chosen from Epilepsy out patient clinic and Neurology department at Assiut University Hospital.

Brief summary: Epilepsy is the second commonest chronic neurological disorder in developed countries, Comorbidity refers to the co-occurrence of two conditions with a greater frequency than found in the general population


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed as primary epilepsy either newly diagnosed or on AEDs
* Aged above 18 years old
* Males and females

Exclusion Criteria:

* Patients diagnosed as secondary epilepsy (post stroke, trauma, tumor, encephalitis, etc).
* Patients diagnosed as epilepsy syndrome

Primary outcomes:
measure: DEXA Scan
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03474484: Calprotectin I Serum as a Diagnostic Marker
Official title: Calprotectin I in Serum as a Diagnostic Marker of Pneumonia in Patients Hospitalised With Acute COPD Exacerbation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pulmonary Disease, Chronic Obstructive
Keywords: Biomarkers
Sensitivity and Specificity
Clinical Deterioration
Lead sponsor: St. Olavs Hospital
Sponsor class: OTHER
Collaborators: name: Norwegian University of Science and Technology
First posted: 2018-03-22
Enrollment: 113
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients admitted to the Department of Thoracic Medicine at Trondheim University Hospital (TUH) due to an AECOPD, age \> 18years old. (EU). The patients were examined at the Emergency Unit and included in the study if they had a COPD diagnosis previously confirmed by spirometry according to the GOLD criteria and a clinically confirmed AECOPD

Brief summary: Lower respiratory tract infection is the most common cause of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Patients diagnosed with pneumonia in addition to an AECOPD experience more severe clinical and laboratory disease manifestations, increase in-hospital morbidity and worse outcome. Clinicians have sought for new biomarkers that together with clinical assessments can improve the diagnostic accuracy of pneumonia in patients with AECOPD.The aim of the present study is to compare the accuracy of calprotectin with procalcitonin (PCT), C-reactive protein (CRP) and white blood cell count (WBC).


Eligibility criteria: Inclusion Criteria:

* clinically confirmed acute exacerbation of chronic obstructive pulmonary disorder (AECOPD)
* COPD diagnosis previously confirmed by spirometry according to the GOLD criteria.

Exclusion Criteria:

* known malignant disease
* bronchiectasis
* chronic bacterial colonisation of the airways
* treatment with an immunosuppressive drug or long-term treatment with antibiotics.
* not examined with a chest X-ray at admission

Primary outcomes:
measure: Calprotectin concentration in serum
timeFrame: Change in serum concentration from baseline to 48 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Trondheim
country: Norway
facility: Department of Thoracic and Occupational Medicine
state: Trøndelag
Study officials:
affiliation: St Olavs Hospital HF
name: Anne h. Henriksen, md phd
role: STUDY_DIRECTOR
References:
citation: Titova E, Aune MW, Fonn K, Henriksen AH, Asberg A. Neutrophil CD64 Expression as a Diagnostic Marker in Patients Hospitalized with Exacerbations of COPD: A Prospective Observational Study. Lung. 2015 Oct;193(5):717-24. doi: 10.1007/s00408-015-9762-2. Epub 2015 Jul 15.